183 related articles for article (PubMed ID: 24691438)
1. Melanoma NOS1 expression promotes dysfunctional IFN signaling.
Liu Q; Tomei S; Ascierto ML; De Giorgi V; Bedognetti D; Dai C; Uccellini L; Spivey T; Pos Z; Thomas J; Reinboth J; Murtas D; Zhang Q; Chouchane L; Weiss GR; Slingluff CL; Lee PP; Rosenberg SA; Alter H; Yao K; Wang E; Marincola FM
J Clin Invest; 2014 May; 124(5):2147-59. PubMed ID: 24691438
[TBL] [Abstract][Full Text] [Related]
2. NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2.
Xu P; Ye S; Li K; Huang M; Wang Q; Zeng S; Chen X; Gao W; Chen J; Zhang Q; Zhong Z; Lin Y; Rong Z; Xu Y; Hao B; Peng A; Ouyang M; Liu Q
J Exp Clin Cancer Res; 2019 Dec; 38(1):483. PubMed ID: 31805977
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE
J Natl Cancer Inst; 2004 Sep; 96(17):1331-42. PubMed ID: 15339971
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of NOS1 promotes the interferon response of melanoma cells.
Chen X; Zou Z; Wang Q; Gao W; Zeng S; Ye S; Xu P; Huang M; Li K; Chen J; Zhong Z; Zhang Q; Hao B; Liu Q
J Transl Med; 2022 May; 20(1):205. PubMed ID: 35538490
[TBL] [Abstract][Full Text] [Related]
5. IFN-alpha-2b-induced signal transduction and gene regulation in patient peripheral blood mononuclear cells is not enhanced by a dose increase from 5 to 10 megaunits/m2.
Zimmerer JM; Lehman AM; Ruppert AS; Noble CW; Olencki T; Walker MJ; Kendra K; Carson WE
Clin Cancer Res; 2008 Mar; 14(5):1438-45. PubMed ID: 18316567
[TBL] [Abstract][Full Text] [Related]
6. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.
Lesinski GB; Trefry J; Brasdovich M; Kondadasula SV; Sackey K; Zimmerer JM; Chaudhury AR; Yu L; Zhang X; Crespin TR; Walker MJ; Carson WE
Clin Cancer Res; 2007 Sep; 13(17):5010-9. PubMed ID: 17785551
[TBL] [Abstract][Full Text] [Related]
7. High density oligonucleotide array analysis of interferon- alpha2a sensitivity and transcriptional response in melanoma cells.
Certa U; Seiler M; Padovan E; Spagnoli GC
Br J Cancer; 2001 Jul; 85(1):107-14. PubMed ID: 11437411
[TBL] [Abstract][Full Text] [Related]
8. The prevalence of interferon-alpha transcription defects in malignant melanoma.
Price KL; Herlyn M; Dent CL; Gewert DR; Linge C
Melanoma Res; 2005 Apr; 15(2):91-8. PubMed ID: 15846141
[TBL] [Abstract][Full Text] [Related]
9. Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells.
Lesinski GB; Zimmerer JM; Kreiner M; Trefry J; Bill MA; Young GS; Becknell B; Carson WE
BMC Cancer; 2010 Apr; 10():142. PubMed ID: 20398276
[TBL] [Abstract][Full Text] [Related]
10. Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines.
Respa A; Bukur J; Ferrone S; Pawelec G; Zhao Y; Wang E; Marincola FM; Seliger B
Clin Cancer Res; 2011 May; 17(9):2668-78. PubMed ID: 21248298
[TBL] [Abstract][Full Text] [Related]
11. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma.
Wong LH; Krauer KG; Hatzinisiriou I; Estcourt MJ; Hersey P; Tam ND; Edmondson S; Devenish RJ; Ralph SJ
J Biol Chem; 1997 Nov; 272(45):28779-85. PubMed ID: 9353349
[TBL] [Abstract][Full Text] [Related]
12. Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24.
Ekmekcioglu S; Mumm JB; Udtha M; Chada S; Grimm EA
Cytokine; 2008 Jul; 43(1):34-44. PubMed ID: 18511292
[TBL] [Abstract][Full Text] [Related]
13. Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions.
Kirkwood JM; Farkas DL; Chakraborty A; Dyer KF; Tweardy DJ; Abernethy JL; Edington HD; Donnelly SS; Becker D
Mol Med; 1999 Jan; 5(1):11-20. PubMed ID: 10072444
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma.
Li Y; Song Y; Li P; Li M; Wang H; Xu T; Yu X; Yu Y; Tai Y; Chen P; Cai X; Wang X; Xiang L; Deng R; Zhang X; Gao L; Wang X; Liu J; Cao F
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152220
[TBL] [Abstract][Full Text] [Related]
15. REST negatively and ISGF3 positively regulate the human STAT1 gene in melanoma.
Amalraj J; Cutler SJ; Ghazawi I; Boyle GM; Ralph SJ
Mol Cancer Ther; 2013 Jul; 12(7):1288-98. PubMed ID: 23598529
[TBL] [Abstract][Full Text] [Related]
16. The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line.
Badgwell B; Lesinski GB; Magro C; Abood G; Skaf A; Carson W
J Surg Res; 2004 Jan; 116(1):129-36. PubMed ID: 14732359
[TBL] [Abstract][Full Text] [Related]
17. IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma.
Lesinski GB; Badgwell B; Zimmerer J; Crespin T; Hu Y; Abood G; Carson WE
J Immunol; 2004 Jun; 172(12):7368-76. PubMed ID: 15187113
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha.
Zimmerer JM; Lesinski GB; Ruppert AS; Radmacher MD; Noble C; Kendra K; Walker MJ; Carson WE
Clin Cancer Res; 2008 Sep; 14(18):5900-6. PubMed ID: 18794103
[TBL] [Abstract][Full Text] [Related]
19. Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma.
Gollob JA; Sciambi CJ; Huang Z; Dressman HK
Cancer Res; 2005 Oct; 65(19):8869-77. PubMed ID: 16204058
[TBL] [Abstract][Full Text] [Related]
20. STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α.
Machiraju D; Moll I; Gebhardt C; Sucker A; Buder-Bakhaya K; Schadendorf D; Hassel JC
Melanoma Res; 2018 Jun; 28(3):204-210. PubMed ID: 29485532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
